A Review on Assurance and Compliance of Manufacturing of Tablets Following ICH Q10
Prashant Nayak1, Abhishek Kumar2*, Raj Kumar Singh¹, Krishnapriya K R2,
M Chandana Adiga2
1Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS),
Department of Pharmaceutics, Mangalore, India.
2Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS),
Department of Pharmaceutical Chemistry, Mangalore, India.
*Corresponding Author E-mail: abhi12bunty@nitte.edu.in
ABSTRACT:
Quality assurance in the pharmaceutical industry aims to ensure that the product that reaches the patient is safe, effective, and of better quality. Product quality is checked by various activities of quality systems such as managerial and technical, including evaluation of pharmaceutical products documentation, performing or reviewing quality-control laboratory tests, and monitoring product performance. Managerial activities include selecting reliable suppliers, preparing contract terms, monitoring supplier performance, and performing inspection trials during the distribution network. Compliance Services assures that the labs are operating within global regulatory requirements. By assuring the provider agrees on the protocols under a single Universal Operational Qualification framework, it will have a comprehensive, automated approach to investigation, documentation, and agreement, streamlining processes across all leading pharmaceutical industry models. In pharmaceutical industries, tablet dosage forms should follow the Q10 guidelines of ICH. The models and statistical approaches should qualify as per the guidelines. Observation should be done throughout the life cycle of the tablet dosage form.
KEYWORDS: Quality assurance, ICH Q10, Tablet.
INTRODUCTION:
ICH Q10 describes a comprehensive model based on ISO for a successful pharmaceutical quality system. During the product lifestyle, this model is applied at various stages. But, the fact that it is not intended to make any new expectations beyond current regulatory requirements cannot be overlooked. Its execution should serve innovation and constant improvement and strengthen the connection between pharmaceutical development and manufacturing activities as ICH Q10 exhibits regulatory authorities and industry support of a remarkable pharmaceutical quality system to progress the quality and availableness of medicines around the global involvement of public health1,2.
The main principle of the pharmaceutical dosage form is to get a therapeutic response to the predicted drug. Physical and chemical stability and suitable microbial contamination prevention are required to maintain product quality. The quality of pharmaceutical products is done by testing the raw materials and equipment. However, a pharmaceutical dosage form is a dynamic product whose visual property, consistency, weight, and chemical identity vary between manufacture and final consumption. The pharmaceutical product that passes all laboratory tests upon receipt may be useless within a few months if packaging and storing are not appropriately done3,4.
Pharmaceutical quality system:
Considering the differences between each stage and its goals, the fundamentals of ICH Q10 will be applied appropriately and proportionately. The pharmaceutical products lifestyle includes Pharmaceutical development, Technology transfer, Commercial manufacturing, and product discontinuation.
ICH Q10 gives the provincial GMP requirements for a blended model throughout a product's lifecycle, which is expected to be utilized together. The provincial GMPs don't expressly address all phases of the product lifestyle.
The three main objectives of the implementation of the Q10 model are to
1. Achieve product realization (foundation, usage) and maintain a framework that permits the conveyance of quality products.
2. Maintaining and establishing the state of control (creating and utilizing successful observation of product quality).
3. Assist continual improvement (distinguishing and performing fitting product quality enhancements)5.
For effective and successful implementation of ICH Q10, the use of knowledge management- formulation and development knowledge should be carried off since evolution during the manufacturing and marketing life of the product till product discontinuation, as well as quality risk management- a valuable pharmaceutical quality system which ensures the products or process which is going to be performed should not have any errors or failure to its quality or procedure by taking proactive measures which are determined scientifically 6.
Its design, organization, and documentation shall be well structured and include suitable procedures, resources, and duties to give confidence in the superior quality of source activities and purchase materials.
The quality manual should include their quality policy, the scope of the pharmaceutical quality system, its identification as well as its sequences, linkages, interdependencies, and management responsibilities, which include management community, quality strategy, quality arranging, asset the executives, interior correspondence, the board survey, the board of redistributed movement and the board of progress in item possession7.
Process performance and product quality and its continual improvement:
As per ICH Q10 objectives, it should describe the stage goals of the life cycle and the elements of the pharmaceutical quality system that augment regional requisites to attain
Lifecycle stage goals:
1. The drug improvement objective is to plan an item and its assembling cycle to convey the planned process reliably.
2. Technology transfer- the objective is to transfer product and process knowledge among assembling and advancement, and between or inside assembling destinations to accomplish product acknowledgment, which frames the reason for the manufacturing process, control methodology, measure approval approach, and progressing final improvement
3. Commercial manufacturing- objectives include a state of control facilitating continual improvement in product realization, establishing and manufacturing.
4. Product discontinuation- scope for a predefined approach should be used to deal with the terminal phase of product lifestyle.
Pharmaceutical quality system elements:
The Q10 models promote advance to product quality which includes four parts.
1. Process performance and product quality monitoring system:
Drug organizations must design and implement a framework, observing the cycle execution and item worth to guarantee a situation of control utilizing the control technique, criticism on item quality, and information to upgrade measure understanding. (Table-1).
2. Corrective action and prevention action (CAPA) system:
The drug institute ought to have a framework for executing remedial and preventive activities because of the inspection of grumblings, item dismissals, reviews, deviations, reviews, administrative investigations, and findings and patterns from measure execution and item quality checking. A structured way to deal with the examination cycle ought to be utilized to decide the main driver8,9.
Table I: Application of process performance and product quality monitoring system throughout the product life cycle
|
Pharmaceutical Development |
Technology Transfer |
Commercial Manufacturing |
Product Discontinuation |
|
Knowledge and monitoring of process and product conducted for the lifecycle will be used in manufacturing as a control strategy. |
Process manufacturing performance which tells preliminary indications by monitoring ongoing scale up activities and this implementation for manufacturing. The control strategy will be developed with the help of scale-up activities with proper planning and regulations. |
The organization must implement a definite arrangement for process performance and product quality monitoring to identify the improvement areas. |
Stability testing must continue even after the cessation of the manufacturing process. Regional regulations must be followed to conduct appropriate studies on the marketed product. |
Table II: Application of Corrective Action and Preventive Action System throughout the Product lifecycle
|
Pharmaceutical Development |
Technology Transfer |
Commercial Manufacturing |
Product Discontinuation |
|
Process fidelity is checked. CAPA is helpful where remedial and preventive actions are consolidated into the iterative plan and advancement measure. |
CAPA can be used as a compelling framework for feedback and continual improvement. |
CAPA has to be implemented, and the feasibility of the activities should be assessed. |
CAPA should proceed after the item is suspended. The result of an item remaining on the market ought to be thought of as different items that may be influenced. |
Table III: Change Management System throughout the Product Lifecycle application
|
Pharmaceutical Development |
Technology Transfer |
Commercial Manufacturing |
Product Discontinuation |
|
Alteration is an intrinsic aspect of the improvement cycle that has to be reported; the convention in a change of executives cycle ought to be reliable with the phase of drug advancement. |
The change management system ought to give the executives recorded data of cycle changes during technology transfer activities. |
A proper change management system will be made for business fabricating. supervision by the quality unit ought to give affirmation of fitting science risk-based assessments |
Any progressions after item cessation ought to experience a proper change management system. |
Table IV: Management Review of Process Performance and Product Quality throughout the Product Lifecycle application
|
Pharmaceutical Development |
Technology Transfer |
Commercial Manufacturing |
Product Discontinuation |
|
Management review is checked for sufficiency of product and process design |
Parts of the management review will be performed to promise that the created item and process can be formed at a business scale. |
As portrayed above, the executive's audit ought to be an organized framework and should uphold consistent improvement. |
The board audit ought to incorporate such things as item security and product quality grumblings. |
3. Change management system:
To assess, endorse, and execute the progressions proposed by the CAPA, an organization should have a successful change in the board framework, which guarantees ceaseless improvement attempted in an ideal and powerful way and gives a serious extent of confirmation that there is no unintended result.
4. Management review of process performance and product quality:
It will confirm cycle management and product class are overseen over the lifecycle. This incorporates consequences in administrative assessments and findings, occasional quality surveys, and any subsequent activities from the past administration audits [10,11].
Pharmaceutical quality system continual improvement:
This guides us to improve the pharmaceutical quality system.
· Management review of the pharmaceutical quality system- It ought to incorporate estimation offs accomplishment of pharmaceutical quality system target and evaluation of execution markers that can be utilized till screen the viability of cycle inside the framework.
· Monitoring of impact on internal and external factors of pharmaceutical quality system- FSA depends on the executives incorporate developing guidelines, direction and quality issues that can affect the framework, advancements that may improve the framework, changes in business climate and goal and changes in formulation possession.
· Management review and monitoring outcomes - This incorporate enhancements to the quality system and processes, assignment or redistribution of assets, corrections of quality picture and target, documentation and powerful correspondence of the consequences of the administration audit and activities, including acceleration of fitting issues to see or the executives[12,13,14].
· Eissa ME et. al. conducted a study and mainly stated that all the pharmaceutical companies depend on the acceptance criterion seh by internal, regulatory and/ or pharmacopeial requirements for the discharge of products for public use. Even though the factual cycle of controlling observation is disparaged by and large, It is likewise significant for consistence with all suitable drug works, including great assembling and lab rehearses known as GXP. The progressing work means examining two tablet assessment attributes checked during process control, viz tablet average weight and hardness. Both this stage were analyzed during the compression and before coating. The quality assurance team gathered the data while commercial Statistical Software packages processed it. Antibacterial tablets: 31 batches screened based on Fluoroquinolone may have the release specifications despite the process being unstable, as evident in the variable control chart. In like manner, the two examined measure were not in the condition of control and require solid activities to address for the rebelliousness to GXP, setting the principles for the application n of SPC ought to be ordered by Regulatory Agencies 15,16.
· Sharma P et. al. conducted a study on “an analytical study of quality management in pharmaceutical industries”. The drug should be of better quality of product as it is directly induced to the human body. Studies have been performed based on the importance of quality management in pharmaceutical industries, including different studies related to this management. The studies and surveys conducted in research work of quality management have recognized the factor to improve the quality of products. Based on n the conclusion of a pharmaceutical company, it was seen that people based on their qualification, had sufficient knowledge to perform their tasks successfully 17.
· Jain SK et. al. studied "Investigations and CAPA: Quality system for continual improvement in pharmaceutical industry". The study demonstrates that with a good and detailed investigations, the rejection of the batches can be avoided while building confidence. An investigator from the USFDA performs regulatory audits for one or three combined reasons. The reasons being- 1) Pre-approval inspection 2) Regular GMP inspection and 3) For cause audit [18].
In case of non compliance, he cites the observation on the form as "FDA 483" and the organization needs to recognize the root cause for the non compliance so as to make corrective action by performing quality risk assessments. In this investigation actions were taken after the non compliance reported, hence preventive action is inapplicable.
· Appleton T et. al. conducted a study on "Nonclinical Dose Formulation: Out of Specification Investigations". It provides recommendations of best practices of non clinical dose formulation OOS investigations. Non-clinical safety studies must follow applicable GLP regulations, and their dose formulations must be analyzed to confirm icefall stability. Those that fall off the acceptance criteria as considered OOS placed with required investigation. US FDA had provided a guidance document for OOS investigation however nothing had been issued for the nonclinical safety study investigations 19.
· Raj A et.al. performed a review study on Corrective Action and Preventive Action (CAPA). A report was made, and the objective is to discuss corrective action and preventive action (CAPA). The CAPA in any pharmaceutical industry controls failures and takes necessary actions to avoid reoccurrence. The CAPA a well takes precautions from the beginning. It is a component of the quality management and is a requirement in the industry [20]
· Kuselman I et.al. conducted study on "Investigating out-of-specification test results of chemical composition based on metrological concepts". After identifying the OOS test result, determining its root cause and avoiding its reluctance is important. The examination dependent on metrological ideas is gainful as it incorporates an assessment of validation data of the measurement process, assessment of their estimation vulnerability commitments, and evaluation of neurological recognizability chains basic for estimation boundaries and ecological conditions affecting the test outcomes. The investigation should answer the questions such as - a) the predefined prerequisites and the validation data of the testing process sufficient for planned use and for assessment of commitments of the related estimation vulnerability, b) on which phase of the testing cycle the estimation vulnerability commitments as predominant and could cause the OOS test results and c) which metrological recognizability chains as broken and could likewise cause the OOS test results. This examination doesn't bargain manage subjective testing, human error or technological problem of the product21.
CONCLUSION:
Based on the ICH Q10 guidelines, it can be concluded that different theories can help maintain the quality of the manufactured tablets. The tablets must be manufactured following the ICH Q10 guidelines through statistical analysis and risk assessment tools.
ACKNOWLEDGEMENT:
The authors are thankful to Nitte (Deemed to be University) for providing the necessary facilities to carry out this research.
REFERENCES:
1. Quality Assurance of Pharmaceuticals. 2nd ed. Geneva: World Health Organization; 2007.
2. Jena S, Arjun G, Kumar DS, Vinod KR et al. Industrial process validation of solid dosage forms-An overview. International Journal of Pharmaceutical Sciences Review and Research. 2010; 4(2): 145-53.
3. Nauman M, Bano R. Implementation of quality risk management (QRM) in pharmaceutical manufacturing industry. IOSR Journal of Pharmacy and Biological Sciences (IOSR-JPBS). 2014; 9(1): 95-101.
4. Reddy VV, Vishal Gupta N, Raghunandan HV, Nitin Kashyap U. Quality risk management in pharmaceutical industry: A review. International Journal of Pharm Tech Research. 2014; 6(3): 908-14.
5. Kumar A, Kumar P, Shravya H, Pai A. Coumarins as potential anticoagulant agents. Research Journal of Pharmacy and Technology. 2022; 15(4): 1659-63. DOI: 10.52711/0974-360X.2022.00277
6. Kumar N, Jha A. Quality risk management during pharmaceutical ‘good distribution practices’–A plausible solution. Bulletin of Faculty of Pharmacy, Cairo University. 2018; 56(1): 18-25. DOI:10.1016/j.bfopcu.2017.12.002
7. Pandey P, Anju G. Quality management system in drug industry: A review. Biomedical Journal of Scientific and Technical Research. 2018; 2(1): 2177-9. DOI: 10.26717/BJSTR.2018.02.000653
8. Bharathy P, Morais SR. Change Control Management: An Overview. Int. J. Life Sci. Pharma Res.2022; 12(1): P79-87. DOI: 10.22376/ijpbs/lpr.2022.12.1.P79-87
9. Wanegaonkar AM, Chaudhari M, Jadhav KR, Kadam VJ. Quality by Design: An Over View in Pharma Industry. Research Journal of Pharmacy and Technology. 2024; 17(7): 3492-8. DOI:10.52711/0974-360X.2024.00546
10. Sharma P. An analytical study of quality management in pharmaceutical industries. International Journal of Management Research and Reviews. 2017; 7(4): 482. DOI:10.14302/issn.2638-4469.japb-17-1534
11. Jain SK, Jain RK. Investigations and CAPA: quality system for continual improvement in pharmaceutical industry. Int J Res Pharm Pharm Sci. 2017; 2: 47-54.
12. Sakkal E, Bitar Y, Trefi S. Quality control of the active Pharmaceutical ingredients of some Pharmaceutical products prior the termination of their shelf life. Research Journal of Pharmacy and Technology. 2019; 12(12): 6111-8. DOI: 10.5958/0974-360X.2019.01062.X
13. Raj A. A review on corrective action and preventive action (CAPA). African Journal of Pharmacy and Pharmacology. 2016; 10(1): 1-6. http://dx.doi.org/10.5897/AJPP2015.4390
14. Wuest T, Irgens C, Thoben KD. An approach to monitoring quality in manufacturing using supervised machine learning on product state data. Journal of Intelligent Manufacturing. 2014; 25: 1167-80. DOI:10.1007/s10845-013-0761-y
15. Das V, Bhairav B, Saudagar RB. Quality by design approaches to analytical method development. Research Journal of Pharmacy and Technology. 2017; 10(9): 3188-94.
16. Aravindan N, Kamaraj R. Change control in pharmaceutical quality management system. Research Journal of Pharmacy and Technology. 2020; 13(4): 1987-90. DOI: 10.5958/0974-360X.2020.00357.1
17. Wanegaonkar AM, Chaudhari M, Jadhav KR, Kadam VJ. Quality by Design: An Over View in Pharma Industry. Research Journal of Pharmacy and Technology. 2024; 17(7): 3492-8. DOI:10.52711/0974-360X.2024.00546
18. Dara SK, Tiwari RN. Pharmaceutical process validation: An industrial perspective. Research Journal of Pharmacy and Technology. 2014; 7(7): 810-4.
19. Shrestha B, Basnett H, Raj PM, Patel SS et al., Process analytical technology: a quality assurance tool. Research Journal of Pharmacy and Technology. 2009; 2(2): 225-7.
20. Kim KW, Lim CH, Joung SH. Analysis of Quality Assurance Items of Film Screen and CR Systems. Research Journal of Pharmacy and Technology. 2017; 10(7): 2106-10. DOI : 10.5958/0974-360X.2017.00368.7
21. Harde M, Lakade S, Wasnik U, Wakade S et al., ICH Guideline in Practice for Quantification of Ruxolitinib by applying Validated RP-HPLC Method on Commercial Tablet Formulation. Research Journal of Pharmacy and Technology. 2024; 17(11): 5242-6.DOI: 10.52711/0974-360X.2024.00802